|
Press Releases |
|
|
|
Tuesday, December 20, 2022 |
|
Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors |
Sirnaomics Ltd. (Stock Code: 2257.HK) (the "Company", together with its subsidiaries, "Sirnaomics" or the "Group"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the interim results from a Phase I clinical trial evaluating the safety more info >> |
|
Wednesday, December 14, 2022 |
|
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the interim results of part-one of an ongoing Phase IIb clinical trial of STP705 for the treatment of Cutaneous Squamous Cell Carcinoma In Situ (isSCC). more info >> |
|
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022 |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Executive Director Dr. Xiaochang Dai will deliver a keynote speech at BIOHK2022, the first major biotech conference to be held in Hong Kong since the outbreak of the COVID-19 pandemic. more info >> |
|
Tuesday, November 8, 2022 |
|
Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the Company has dosed the first patient in a Phase I clinical study of STP705, a siRNA (small interfering RNA) drug candidate, for the study of fat reduction in adults undergoing abdominoplasty. more info >> |
|
Wednesday, October 19, 2022 |
|
Sirnaomics to Present Latest Developments on GalAhead(TM) Therapeutic Platform at Upcoming Industry Conferences |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK) a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on GalAhead(TM), a GalNAc-RNAi therapeutic platform, and its pipeline programs, at two industry conferences in Boston more info >> |
|
Tuesday, September 20, 2022 |
|
Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics more info >> |
|
Tuesday, September 6, 2022 |
|
Sirnaomics to Present at 3rd Annual Jefferies Asia Forum |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today more info >> |
|
Monday, August 29, 2022 |
|
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the cohort receiving the 180ug dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response (CR) more info >> |
|
Friday, August 26, 2022 |
|
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead(TM) RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases. more info >> |
|
Monday, August 22, 2022 |
|
Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes |
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company has been selected as a constituent stock of eight index series including Hang Seng Composite Index ("HSCI") more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation
May 17, 2024 22:29 HKT/SGT
|
|
|
Top executives from SDAIA, Saudi Aramco, Almarai, Saudi Pro League & many others coming to speak at Smart Data & AI Summit
May 17, 2024 20:09 HKT/SGT
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 17, 2024 18:00 HKT/SGT
|
|
|
CITIC Telecom CPC's Innovation Excellence Honored with 2 Innovation Awards
May 17, 2024 16:37 HKT/SGT
|
|
|
London Climate Technology Show 2024 Returns For Third Edition at ExCeL London
May 17, 2024 15:48 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning
May 17, 2024 14:03 JST
|
|
|
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
|
|
|
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
May 16, 2024 22:00 HKT/SGT
|
|
|
DEXIS Innovation Continues With New DEXIS Ti2 Sensor as Successor to the DEXIS Titanium Sensor, the #1 Selling Intraoral Sensor in the United States
May 16, 2024 21:30 HKT/SGT
|
|
|
Horus: Million Dollar Air-Mail NFT Drop on Base
May 16, 2024 20:11 HKT/SGT
|
|
|
HKTDC kicks off third International Healthcare Week
May 16, 2024 18:00 HKT/SGT
|
|
|
CleverTap's 2024 Market Research Report Unveils that Brands Implementing Higher AI Adoption See 4x Boost in Conversions
May 16, 2024 17:00 HKT/SGT
|
|
|
Q2 Metals Announces Re-Assay Results and Spring 2024 Exploration Plan for Cisco Lithium Property, James Bay Territory, Quebec, Canada
May 16, 2024 15:09 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|